Accenture Expands Strategy Capabilities in Life Sciences with the Acquisition of Bionest
Scientific and technological advancements are creating breakthroughs for patient health, resulting in more complex and personalized therapies. This dynamic combination of the best in science and health technology is expected to drive 81 percent of biopharma revenue growth.
However, biopharma companies must also juggle increasingly complex commercialization challenges, patient access issues, and a changing regulatory and economic environment to achieve that growth Complex areas of science require novel thinking when it comes to how businesses consider their go-to-market strategy.
Bionest’s team of 46 scientifically-minded consultants, industry executives, and specialists are experts at addressing complex strategic decisions for leading biopharma organizations across innovative areas of science including precision medicine and diagnostics, oncology, cell & gene therapy, and rare diseases.
Accenture is a leading global professional services company with 738,000 people serving clients in more than 120 countries, helping the world’s leading businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services.
Together, we’ll be able to bring new capabilities to our clients through strategy development and operational execution in some of the most exciting areas of science.